The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Cell Dev. Biol.
Sec. Cancer Cell Biology
Volume 12 - 2024 |
doi: 10.3389/fcell.2024.1421981
This article is part of the Research Topic Therapeutic Potential Affected by Tumor Microenvironment in Triple-Negative Breast Cancer View all 5 articles
Evaluation of prognostic risk factors of triple-negative breast cancer with 18 F-FDG PET/CT parameters, clinical pathological features and biochemical indicators
Provisionally accepted
Zhu Lei
1
Xin Yang
2
Jiying Zhang
2*
Shuling Wang
2*
Yulong Wang
2
Xing Wan
1
Xiang Zhu
1*
Xiuyu Song
1*
Zhongsheng Tong
2*
Meng Yang
3*
Weipeng Zhao
2*- 1 Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- 2 Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- 3 Laboratory of Cancer Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Abstract Objective: Breast cancer is a heterogeneous disease comprising various molecular subtypes, including luminal A, luminal B, human epidermal growth factor receptor-2 (HER2) positive, and triple negative types, each with distinct biological characteristics and behaviors. Triple negative breast cancer (TNBC) remains a particularly challenging subtype worldwide. This study aims to evaluate whether Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) parameters, clinical pathological features, and biochemical indicators serve as prognostic risk factors for TNBC. Additionally, we explore correlations between biochemical indicators and 18F-FDG PET/CT parameters. Materials and methods: We conducted a retrospective analysis of 95 TNBC patients who underwent preoperative 18F-FDG PET/CT examinations at Tianjin Medical University Cancer Institute & Hospital from 2013 to 2018. Collected data included 18F-FDG PET/CT parameters, clinical and pathological features, and biochemical indicators. We used Kaplan-Meier survival analysis and multivariate Cox regression analysis to evaluate associations between 18F-FDG PET/CT parameters /biochemical indicators and disease free survival (DFS)/overall survival (OS). The log-rank test determined significant differences in survival curves, and the Spearman correlation coefficient analyzed correlations between quantitative variables. Visualization and analysis were performed using R packages. Results: Among 95 TNBC patients, mean standardized uptake value (SUVmean) was significantly correlated with DFS. Fasting blood glucose (FBG), α- L-fucosylase (AFU) and Creatine kinase (CK) were independent predictors of DFS, while Precursor albumin(PALB) and CK were independent predictors of OS. FBG showed correlations with SUVpeak and SUVmean, and CK was correlated with peak standardized uptake value (SUVpeak). Our results indicated that 18F-FDG PET/CT parameters and biochemical indicators may constitute a new prognostic model for TNBC patients post-surgery. Conclusion: SUVmean, FBG, AFU and CK are predictive factors for DFS in TNBC patients post-surgery, while PALB and CK are predictive factors for OS, which prompts us to pay more attention to these indicators in clinical practice. And 18F-FDG PET/CT parameters and biochemical indicators have potential utility in constituting a new prognostic model for TNBC patients post-surgery.
Keywords: TNBC, 18 F-FDG PET/CT, Clinical pathological features, Biochemical indicators, prognosis
Received: 23 Apr 2024; Accepted: 23 Aug 2024.
Copyright: © 2024 Lei, Yang, Zhang, Wang, Wang, Wan, Zhu, Song, Tong, Yang and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jiying Zhang, Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Shuling Wang, Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Xiang Zhu, Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300070, China
Xiuyu Song, Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300070, China
Zhongsheng Tong, Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Meng Yang, Laboratory of Cancer Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Weipeng Zhao, Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.